Spruce Biosciences, Inc.
SPRB · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -20,438.79% | -7,875.38% | -9,412.59% | -3,709.50% |
| EV / EBITDA | 7.15 | 1.65 | 1.52 | 6.59 |
| Quality | ||||
| ROIC | -17.94% | -82.25% | -75.54% | -17.06% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.65 | 4.27 | 0.91 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -54.09% | -31.99% | 13.99% | 1,699,669.29% |
| Free Cash Flow Growth | 30.64% | 38.45% | -124.19% | 16.95% |
| Safety | ||||
| Net Debt / EBITDA | 7.17 | 1.67 | 1.53 | 6.62 |
| Interest Coverage | -92.83 | -402.56 | -429.89 | -132.51 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |